This Practice Alert highlights some recent practice issues reported to PDL Professional Officers.
Respiratory Syncytial Virus (RSV) vaccines
Currently, two Respiratory Syncytial Virus (RSV) vaccines, Arexvy® and Abrysvo®, have been approved by the Therapeutic Goods Administration (TGA) for protecting adults against RSV disease. Recent government-led vaccination campaigns have highlighted the benefits of immunisation against RSV infection, resulting in increased patient uptake of these vaccines.
A single dose of Arexvy or Abrysvo is recommended for:
People aged 75 years and over
…
